Jasper Therapeutics (JSPR) Liabilities and Shareholders Equity (2019 - 2026)

Jasper Therapeutics has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $11.8 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 74.6% year-over-year to $11.8 million in Q2 2026; TTM through Jun 2026 was $151.5 million, a 46.53% decrease from a year earlier, with the FY2025 full-year figure at $35.8 million, down 55.22% from the prior year.
• Liabilities and Shareholders Equity was $11.8 million for Q2 2026 at Jasper Therapeutics, down from $35.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $138.8 million in Q1 2023, with the low at $11.8 million in Q2 2026.
• Average Liabilities and Shareholders Equity over 5 years is $79.7 million, with a median of $79.9 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity soared 96.22% in 2023, then slumped 74.6% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $48.4 million in 2022, then surged by 96.22% to $94.9 million in 2023, then fell by 15.8% to $79.9 million in 2024, then slumped by 55.22% to $35.8 million in 2025, then sank by 67.01% to $11.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $11.8 million (Q2 2026), $35.8 million (Q4 2025), and $57.5 million (Q3 2025), per Business Quant data.